menu
    • menu
    [{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"Il-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"Il-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"TYK","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"kinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Onco360","sponsor":"CTI BioPharma Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onco360 \/ CTI BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ CTI BioPharma"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/IRAK1","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":1.7,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":1.7,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Pacritinib

    Menu

    Pacritinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BerGenBio ASA

                            Norway arrow
                            BioAsia
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemcentinib,Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

                            Details : BGB 324 (bemcentinib) is an AXL inhibitor in combination with pacritinib, which is a JAK2 inhibitor is being investigated in patients with advanced adenocarcinoma lung cancer.

                            Product Name : BGB 324

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : Bemcentinib,Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $1,700.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sobi Completes Acquisition of CTI BioPharma Corp.

                            Details : The acquisition strengthens Sobi’s leading haematology franchise by adding Vonjo (pacritinib), a novel oral kinase inhibitor that inhibits JAK2, IRAK1 and ACRV1, while sparing JAK1, for the treatment of adults with myelofibrosis. Vonjo obtained acceler...

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : $1,700.0 million

                            June 26, 2023

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $1,700.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $1,700.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sobi to Acquire CTI BioPharma

                            Details : The acquisition will diversify Sobi's portfolio of leading hematology medicines through CTI's lead product, VONJO® (pacritinib), which is FDA-approved for the treatment of adult myelofibrosis patients with a platelet count below 50 x109/L.

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : $1,700.0 million

                            May 10, 2023

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : $1,700.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and ...

                            Details : Vonjo (Pacritinib) is an oral kinase inhibitor with activity against wild type Janus Associated Kinase 2 (JAK2), mutant JAK2V617F form, IRAK1, ACVR1 (ALK2) and FMS-like tyrosine kinase 3 (FLT3).

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hema...

                            Details : On duplicate assays, Vonjo (pacritinib) was shown to be a more potent inhibitor of ACVR1 compared to momelotinib, with a half maximal inhibitory concentration (IC50) of 10.8 and 22.6 nM versus34.9 and 70.2 nM, respectively.

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2022

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CTI BioPharma Presents Pivotal Data from Pacritinib Program at the European Hematology Association (EHA) 2022 ...

                            Details : Vonjo (pacritinib) is an oral kinase inhibitor with activity against wild type JAK2, mutant JAK2V617F form and FMS-like tyrosine kinase 3 (FLT3), which contribute to signaling of a number of cytokines and growth factors that are important for hematopoies...

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2022

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology ...

                            Details : Vonjo (Pacritinib) is an oral kinase inhibitor with activity against wild type JAK2, mutant JAK2V617F form and FMS-like tyrosine kinase 3, which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and ...

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 27, 2022

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NCCN Guidelines® Recommend VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

                            Details : At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1), the clinical relevance of which is unknown.

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 14, 2022

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Onco360

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : CTI BioPharma Corp

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VONJO™ (pacritinib) Now Approved for the Treatment of Adults with Intermediate or High-Risk Primary or Secon...

                            Details : FDA’s approval of VONJO (pacritinib) is based upon results of PERSIST-2 clinical trial indicate that 29% of myelofibrosis patients with baseline platelet levels of less than 50 x 109/L obtained spleen volume reductions of at least 35% during first six ...

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 04, 2022

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : CTI BioPharma Corp

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            CTI BioPharma Corp

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (Pacritinib) for the Treatment of Adult Patients ...

                            Details : Vonjo (pacritinib), is an oral kinase inhibitor with activity against wild type JAK2, mutant JAK2V617F form and FLT3, contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.

                            Product Name : Vonjo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2022

                            Lead Product(s) : Pacritinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth